Skip to content

Alzheimer's Disease: Potential Benefit of Isoflavones

Alzheimer's Disease: Potential Benefit of Isoflavones

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00205179
Enrollment
72
Registered
2005-09-20
Start date
2005-01-31
Completion date
2009-12-31
Last updated
2020-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

The purpose of this pilot study is to evaluate the potential effects of soy isoflavone supplements on cognitive function for men and women with Alzheimer's Disease (AD). Preliminary studies evaluating the effects of soy supplements on memory in cognitively healthy older adults have yielded promising results that are now being evaluated in patients with AD. It is hypothesized that isoflavone supplements will ameliorate cognitive declines for older adults diagnosed with Alzheimer's disease, when compared to subjects on placebo.

Interventions

100mg/day soy isoflavones

DRUGPlacebo

100mg/day matching placebo

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
National Institute on Aging (NIA)
CollaboratorNIH
University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of probable AD * Has reliable and available caregiver to assist with medication and appointments * On a stable dose of cholinesterase inhibitor, or if unable to tolerate medication, patient has no plans to re-initiate cholinergic therapies while in the study

Exclusion criteria

* Current or recent use (\<6 months) of menopausal Hormone Replacement Therapy (HRT) * Current or recent use (\<4 months) or oral antibiotic therapy * Typical dietary intake of soy isoflavones \>5 mg/day * History or significant gastro-intestinal or colon disease, or colon/intestinal resection * Irritable bowel syndrome * History of breast cancer, or abnormal mammogram within 12 months * History of chronic obstructive pulmonary disease, diabetes mellitus, liver disease or unstable ischemic heart disease * Significant neurological disease other than AD that might affect cognitive function, such as stroke, Parkinson's disease, multiple sclerosis, or serious traumatic brain injury

Design outcomes

Primary

MeasureTime frameDescription
Cognitive Outcomes - Language Executive Function : Category Fluency Assessed as Number of Words Generated/Min6 monthsParticipants are given 1 min to produce as many unique words as possible within a category (category fluency). More words per minute will correlates to better category fluency
Cognitive Outcomes - Language Executive Function : Phonemic Fluency/Verbal Fluency Assessed as Number of Words Generated Per Minute6 monthsParticipants are given 1 min to produce as many words as possible starting with a given letter (letter fluency). More number of words per minute correlates to better phonemic fluency/verbal fluency
Immediate and Delayed Recall on Verbal Memory/ List Learning Immediate and Delayed Free Recall: Number of Words Recalled6 monthsList of 15 semantically unrelated words is presented verbally to the participants once, after which they are asked to free recall as many words as possible. Subsequently, this presentation-test routine (learning trials) is repeated four more times. A total recall score is determined by adding the number of recalled items for the five learning trials. After presentation of a distractor list and a delay of approximately 20 minutes, participants are asked to freely recall items from the original word list. A delayed recall score is then derived from this test.
Immediate and Delayed Recall on Verbal Memory/ Logical Memory Immediate and Delayed Recall: Number of Story Elements Recalled6 monthsIn the logical delayed memory test, participants are read a logically organized story. Approximately 20 minutes later, the participants are asked to recall the story from memory (Delayed Recall). The version used in this study uses only one story (Story A) read once to participants at each study visit. Possible scores for delayed recall trials range from 0 to 25, with higher scores reflecting more details recalled.
Measure of Divided Attention: Time to Complete Trail Making Test B6 monthsTrail Making Test-Version B (TMT B) \[113\], a measure of divided attention, the subject is asked to draw lines to connect consecutively numbered and lettered circles, alternating between the 2 sequences. The time needed to complete the task is recorded. More time taken to complete the test or higher score indicates lower executive function/higher impairment.
A Test of Planning: Time to Complete Mazes6 monthsTime to complete mazes is a test of planning. Subjects are asked to complete a set of 3 mazes. The time taken to complete the maze is inversely proportional to the cognitive function.
Measure of Selective Attention: Time to Complete Stroop Color Word Test6 monthsSelective attention was evaluated with the Stroop Color Word Interference Test. In the interference portion of this test, the subject identifies the color of ink in which words (red, green, or blue) are printed, requiring the subject to inhibit their natural tendency to read the word. A subject's score is the time taken to identify 50 stimulus items. The time taken to complete the maze is inversely proportional to the cognitive function.
Visual Memory Test: Complex Figure Delayed Recall; Number of Points6 monthsVisual memory will be evaluated by complex figure delayed recall test. In this test , a two dimensional figure is shown to the subjects. After a delay of 30 min, they are asked to draw the same figure based on their memory. The Complex Figure Test assesses the subject's ability to remember a 2-dimensional figure presented briefly. The scoring system used includes scores related to location, accuracy and organization. Higher score correlates to better visual memory.
Visual Memory : Benton Visual Retention Test: Number of Correct Figures6 monthsThe Benton Visual Retention Test (or simply Benton test or BVRT) is an individually administered test for people aged from 8 years to adulthood that measures visual perception and visual memory. It can also be used to help identify possible learning disabilities among other afflictions that might affect an individual's memory. The individual examined is shown 10 designs, one at a time, and asked to reproduce each one as exactly as possible on plain paper from memory. The test is untimed, and the results are professionally scored by form, shape, pattern, and arrangement on the paper. For the 'test of number of correct figures' score is calculated based on an all-or-nothing approach; points are awarded if the reproduction of the design matches the original.
Cognitive Outcomes - Visual Memory : Benton Visual Retention; Number of Errors6 monthsThe Benton Visual Retention Test is an individually administered test for people aged from 8 years to adulthood that measures visual perception and visual memory. It can also be used to help identify possible learning disabilities among other afflictions that might affect an individual's memory. The individual examined is shown 10 designs, one at a time, and asked to reproduce each one as exactly as possible on plain paper from memory. The test is untimed, and the results are professionally scored by form, shape, pattern, and arrangement on the paper. For the 'test of number of errors' score is calculated based on the number and type of errors made for each design. The major categories for these errors are omissions, distortions, perseverations, rotations, misplacements, and size errors.These scores are then be compared to several sets of normative data available in the manual, each representing different demographic characteristics, and conclusions can be drawn by the examiner.

Secondary

MeasureTime frameDescription
Geriatric Depression Scale-Subject Report6 monthsGeriatric Depression Scale (GDS) has been tested and used extensively with the older population to measure depression. Subject will self-report a short form GDS consisting of 15 questions. Out of 15 items, 10 indicate the presence of depression when answered positively, while the rest (question numbers 1, 5, 7, 11, 13) indicate depression when answered negatively. Scores of 0-4 are considered normal, depending on age, education, and complaints; Scores of 5-8 indicate mild depression; 9-11 indicate moderate depression; and Scores of 12-15 indicate severe depression. The Short Form is more easily used by physically ill and mildly to moderately demented patients who have short attention spans and/or feel easily fatigued. It takes about 5 to 7 minutes to complete
Geriatric Depression Scale-Study Partner Report6 monthsStudy partner is someone who has frequent contact with the subject (e.g. an average of 10 hours per week or more), and can accompany the subject to all clinic visits for the duration of the protocol. Study partner will report a short form GDS consisting of 15 questions. Out of 15 items, 10 indicate the presence of depression when answered positively, while the rest (question numbers 1, 5, 7, 11, 13) indicate depression when answered negatively. Scores of 0-4 are considered normal, depending on age, education, and complaints; Scores of 5-8 indicate mild depression; 9-11 indicate moderate depression; and Scores of 12-15 indicate severe depression. The Short Form is more easily used by physically ill and mildly to moderately demented patients who have short attention spans and/or feel easily fatigued. It takes about 5 to 7 minutes to complete.
Number of Participants With ApoE4 AlleleBaselineThe epsilon-4 allele of the apolipoprotein E gene (APOE4) has been consistently associated with a greater risk of Alzheimer's disease (AD) as well as an earlier onset of AD. Determination of apolipoprotein E (APOE) genotype was performed on a non-fasting blood sample collected at Baseline, using standard Polymerase chain reaction (PCR) and DNA sequencing techniques in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. DNA extracted from whole blood was amplified by PCR using specific primers for the ApoE gene and the DNA then sequenced and analyzed for genotype using the FinchTV program (Version 1.3; Geospiza, Inc.)
Plasma Concentrations of Isoflavones at BaselinebaselineIsoflavone assays will be performed on non-fasting blood samples collected at baseline. Novasoy capsules predominantly contain purified glycoside forms of isoflavones known genistein and diadzein. The plasma level of genistein and diadzine will be measured in the participants plasma.There is large inter-individual variations in the extent of intestinal metabolism, even when the quantity of isoflavone intake is standardized. Equol is a metabolite of isoflavones. Equol has high biological efficacy. Therefore, along with genistein and diadzein, plasma levels of equol will be measured to understand the isoflavone metabolism in the participants.
Cognitive Outcomes - Visual Motor : Complex Figure Copy; Number of Points6 monthsVisual memory will be evaluated by Complex Figure copy test. The Complex Figure Test assesses the subject's ability to copy a 2-dimensional figure. The scoring system used include scores related to location, accuracy and organization. Higher score correlates to better visual memory.
Plasma Concentrations of Isoflavones at Month 6At month 6Isoflavone assays will be performed on non-fasting blood samples collected at month 6. Novasoy capsules predominantly contain purified glycoside forms of isoflavones known genistein and diadzein. The plasma level of genistein and diadzine will be measured in the participants plasma.There is large inter-individual variations in the extent of intestinal metabolism, even when the quantity of isoflavone intake is standardized. Equol is a metabolite of isoflavones. Equol has high biological efficacy. Therefore, along with genistein and diadzein, plasma levels of equol will be measured to understand the isoflavone metabolism in the participants.
Plasma Concentrations of Estradiol at BaselinebaselineEstradiol assay will be performed on non-fasting blood samples collected at baseline using an enzyme immunoassay kit.
Plasma Concentrations of Estradiol at 3 MonthAt 3 monthEstradiol assay will be performed on non-fasting blood samples collected at baseline using an enzyme immunoassay kit.
Plasma Concentrations of Estradiol at 6 MonthAt 6 monthEstradiol assay will be performed on non-fasting blood samples collected at baseline using an enzyme immunoassay kit.
Plasma Concentrations of Isoflavones at Month 3At month 3Isoflavone assays will be performed on non-fasting blood samples collected at month 3. Novasoy capsules predominantly contain purified glycoside forms of isoflavones known genistein and diadzein. The plasma level of genistein and diadzine will be measured in the participants plasma.There is large inter-individual variations in the extent of intestinal metabolism, even when the quantity of isoflavone intake is standardized. Equol is a metabolite of isoflavones. Equol has high biological efficacy. Therefore, along with genistein and diadzein, plasma levels of equol will be measured to understand the isoflavone metabolism in the participants.
Cognitive Outcomes - Visual Motor : Time to Complete Grooved Pegboard Test Using the Dominant Hand6 monthsThe Grooved Pegboard is a dexterity test consisting of 25 holes with randomly positioned slots. Pegs with a key on one side must be rotated to match the hole before they can be inserted. Participants are instructed to place all pegs into the 25 holes, picking up one at a time, and using just one hand. They use their dominant hand. Time taken to finish the test inversely correlates to the cognitive ability.
Cognitive Outcomes - Visual Motor : Time to Complete Grooved Pegboard Test Using the Non-Dominant Hand6 monthsThe Grooved Pegboard is a dexterity test consisting of 25 holes with randomly positioned slots. Pegs with a key on one side must be rotated to match the hole before they can be inserted. Participants are instructed to place all pegs into the 25 holes, picking up one at a time, and using just one hand. They use their non-dominant hand. Time taken to finish the test inversely correlates to the cognitive ability.
Cognitive Outcomes-Global Cognition : Mini-Mental State Examination (MMSE) Score6 monthsDuring the MMSE, a health professional asks a participant a series of questions designed to test memory, ability to solve simple problems and other thinking skills. The maximum MMSE score - 30 points. Score of 20 to 24 - mild dementia, 13 to 20 - moderate dementia, and \<12 indicates severe dementia. On average, the MMSE score of a person with Alzheimer's declines about 2 to 4 points each year.
Multiple Mood States: Profile of Mood States (POMS)-Depression Scale6 monthsDepression scale is one of the subscale of POMS. Depression scale has 15 items and scores ranges from 0-60. Higher score indicates more severe depression.
Multiple Mood States: Profile of Mood States (POMS)-Tension Scale6 monthsTension scale is one of the subscale of POMS. Tension scale has 9 items and scores ranges from 0-36. Higher score indicates more severe outcomes.
Multiple Mood States: Profile of Mood States (POMS)-Anger Scale6 monthsAnger scale is one of the subscale of POMS. Tension scale has 12 items and scores ranges from 0-48. Higher score indicates more anger issues.
Multiple Mood States: Profile of Mood States (POMS)-Fatigue Scale6 monthsFatigue scale is one of the subscale of POMS. Tension scale has 7 items and scores ranges from 0-28. Higher score indicates more fatigue.
Multiple Mood States: Profile of Mood States (POMS)-Vigor Scale6 monthsVigor scale is one of the subscale of POMS. Vigor scale has 8 items and scores ranges from 0-32. Higher score indicates more severe outcomes.
Multiple Mood States: Profile of Mood States (POMS)-Confusion Scale6 monthsConfusion scale is one of the subscale of POMS. Confusion scale has 7 items and scores ranges from 0-28. Higher score indicates more severe outcomes.

Countries

United States

Participant flow

Pre-assignment details

4 subjects withdrew consent; 3 subjects ineligible due to abnormal laboratory tests or inability to complete testing

Participants by arm

ArmCount
Placebo
100mg/day matching placebo Placebo: 100mg/day matching placebo
33
Novasoy
100mg/day soy isoflavones Novasoy: 100mg/day soy isoflavones
32
Total65

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event11
Overall StudyDeath02
Overall StudyPhysician Decision11

Baseline characteristics

CharacteristicNovasoyTotalPlacebo
Age, Continuous75.7 years
STANDARD_DEVIATION 7.7
76 years
STANDARD_DEVIATION 7
76.8 years
STANDARD_DEVIATION 6.8
Body Mass Index27.5 kg/m^2
STANDARD_DEVIATION 5
27.7 kg/m^2
STANDARD_DEVIATION 5.2
27.9 kg/m^2
STANDARD_DEVIATION 5.4
Education in years14.8 years
STANDARD_DEVIATION 2.7
14.5 years
STANDARD_DEVIATION 2.6
14.2 years
STANDARD_DEVIATION 2.5
Global cognition: Mini-Mental State Examination score23.5 score on a scale
STANDARD_DEVIATION 4
22.95 score on a scale
STANDARD_DEVIATION 4.65
22.4 score on a scale
STANDARD_DEVIATION 5.3
Mood symptoms: Geriatric Depression Scale-Short Form score3.2 score on scale
STANDARD_DEVIATION 3.3
2.9 score on scale
STANDARD_DEVIATION 2.85
2.6 score on scale
STANDARD_DEVIATION 2.4
Number of participants on Acetylcholinesterase-Inhibitors (AchE-I)31 Participants61 Participants30 Participants
Number of participants on N-methyl-D-aspartate receptor (NMDAR) blocker-Memantine16 Participants30 Participants14 Participants
Number of participants with Apolipoprotein E4 (ApoE4) allele16 Participants31 Participants15 Participants
Race/Ethnicity, Customized
Latino
1 participants1 participants0 participants
Race/Ethnicity, Customized
White
31 participants64 participants33 participants
Region of Enrollment
United States
32 participants65 participants33 participants
Sex: Female, Male
Female
17 Participants34 Participants17 Participants
Sex: Female, Male
Male
15 Participants31 Participants16 Participants
Total weekly isoflavone intake at Baseline16.5 mg/week
STANDARD_DEVIATION 66.3
12.5 mg/week
STANDARD_DEVIATION 45.2
6.5 mg/week
STANDARD_DEVIATION 34.1

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
25 / 3223 / 33
serious
Total, serious adverse events
1 / 323 / 33

Outcome results

Primary

A Test of Planning: Time to Complete Mazes

Time to complete mazes is a test of planning. Subjects are asked to complete a set of 3 mazes. The time taken to complete the maze is inversely proportional to the cognitive function.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboA Test of Planning: Time to Complete Mazes32.2 SecondsStandard Error 5.3
NovasoyA Test of Planning: Time to Complete Mazes22.6 SecondsStandard Error 5.4
Primary

Cognitive Outcomes - Language Executive Function : Category Fluency Assessed as Number of Words Generated/Min

Participants are given 1 min to produce as many unique words as possible within a category (category fluency). More words per minute will correlates to better category fluency

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboCognitive Outcomes - Language Executive Function : Category Fluency Assessed as Number of Words Generated/Min21.5 number of words generated per minuteStandard Error 1.9
NovasoyCognitive Outcomes - Language Executive Function : Category Fluency Assessed as Number of Words Generated/Min25.7 number of words generated per minuteStandard Error 2
Primary

Cognitive Outcomes - Language Executive Function : Phonemic Fluency/Verbal Fluency Assessed as Number of Words Generated Per Minute

Participants are given 1 min to produce as many words as possible starting with a given letter (letter fluency). More number of words per minute correlates to better phonemic fluency/verbal fluency

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboCognitive Outcomes - Language Executive Function : Phonemic Fluency/Verbal Fluency Assessed as Number of Words Generated Per Minute25.9 number of words generated per minuteStandard Error 2.4
NovasoyCognitive Outcomes - Language Executive Function : Phonemic Fluency/Verbal Fluency Assessed as Number of Words Generated Per Minute35.2 number of words generated per minuteStandard Error 2.4
Primary

Cognitive Outcomes - Visual Memory : Benton Visual Retention; Number of Errors

The Benton Visual Retention Test is an individually administered test for people aged from 8 years to adulthood that measures visual perception and visual memory. It can also be used to help identify possible learning disabilities among other afflictions that might affect an individual's memory. The individual examined is shown 10 designs, one at a time, and asked to reproduce each one as exactly as possible on plain paper from memory. The test is untimed, and the results are professionally scored by form, shape, pattern, and arrangement on the paper. For the 'test of number of errors' score is calculated based on the number and type of errors made for each design. The major categories for these errors are omissions, distortions, perseverations, rotations, misplacements, and size errors.These scores are then be compared to several sets of normative data available in the manual, each representing different demographic characteristics, and conclusions can be drawn by the examiner.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboCognitive Outcomes - Visual Memory : Benton Visual Retention; Number of Errors14.5 Number of errorsStandard Error 1.2
NovasoyCognitive Outcomes - Visual Memory : Benton Visual Retention; Number of Errors13.1 Number of errorsStandard Error 1.2
Primary

Immediate and Delayed Recall on Verbal Memory/ List Learning Immediate and Delayed Free Recall: Number of Words Recalled

List of 15 semantically unrelated words is presented verbally to the participants once, after which they are asked to free recall as many words as possible. Subsequently, this presentation-test routine (learning trials) is repeated four more times. A total recall score is determined by adding the number of recalled items for the five learning trials. After presentation of a distractor list and a delay of approximately 20 minutes, participants are asked to freely recall items from the original word list. A delayed recall score is then derived from this test.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboImmediate and Delayed Recall on Verbal Memory/ List Learning Immediate and Delayed Free Recall: Number of Words Recalled1.8 Number of words recalledStandard Error 0.5
NovasoyImmediate and Delayed Recall on Verbal Memory/ List Learning Immediate and Delayed Free Recall: Number of Words Recalled2.2 Number of words recalledStandard Error 0.5
Primary

Immediate and Delayed Recall on Verbal Memory/ Logical Memory Immediate and Delayed Recall: Number of Story Elements Recalled

In the logical delayed memory test, participants are read a logically organized story. Approximately 20 minutes later, the participants are asked to recall the story from memory (Delayed Recall). The version used in this study uses only one story (Story A) read once to participants at each study visit. Possible scores for delayed recall trials range from 0 to 25, with higher scores reflecting more details recalled.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboImmediate and Delayed Recall on Verbal Memory/ Logical Memory Immediate and Delayed Recall: Number of Story Elements Recalled4.6 Number of story elements recalledStandard Error 0.95
NovasoyImmediate and Delayed Recall on Verbal Memory/ Logical Memory Immediate and Delayed Recall: Number of Story Elements Recalled5.7 Number of story elements recalledStandard Error 0.9
Primary

Measure of Divided Attention: Time to Complete Trail Making Test B

Trail Making Test-Version B (TMT B) \[113\], a measure of divided attention, the subject is asked to draw lines to connect consecutively numbered and lettered circles, alternating between the 2 sequences. The time needed to complete the task is recorded. More time taken to complete the test or higher score indicates lower executive function/higher impairment.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboMeasure of Divided Attention: Time to Complete Trail Making Test B95.5 SecondsStandard Error 16.7
NovasoyMeasure of Divided Attention: Time to Complete Trail Making Test B95.7 SecondsStandard Error 16
Primary

Measure of Selective Attention: Time to Complete Stroop Color Word Test

Selective attention was evaluated with the Stroop Color Word Interference Test. In the interference portion of this test, the subject identifies the color of ink in which words (red, green, or blue) are printed, requiring the subject to inhibit their natural tendency to read the word. A subject's score is the time taken to identify 50 stimulus items. The time taken to complete the maze is inversely proportional to the cognitive function.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboMeasure of Selective Attention: Time to Complete Stroop Color Word Test105 SecondsStandard Error 12
NovasoyMeasure of Selective Attention: Time to Complete Stroop Color Word Test91.8 SecondsStandard Error 12
Primary

Visual Memory : Benton Visual Retention Test: Number of Correct Figures

The Benton Visual Retention Test (or simply Benton test or BVRT) is an individually administered test for people aged from 8 years to adulthood that measures visual perception and visual memory. It can also be used to help identify possible learning disabilities among other afflictions that might affect an individual's memory. The individual examined is shown 10 designs, one at a time, and asked to reproduce each one as exactly as possible on plain paper from memory. The test is untimed, and the results are professionally scored by form, shape, pattern, and arrangement on the paper. For the 'test of number of correct figures' score is calculated based on an all-or-nothing approach; points are awarded if the reproduction of the design matches the original.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboVisual Memory : Benton Visual Retention Test: Number of Correct Figures2.7 number of correct figuresStandard Error 0.4
NovasoyVisual Memory : Benton Visual Retention Test: Number of Correct Figures2.8 number of correct figuresStandard Error 0.4
Primary

Visual Memory Test: Complex Figure Delayed Recall; Number of Points

Visual memory will be evaluated by complex figure delayed recall test. In this test , a two dimensional figure is shown to the subjects. After a delay of 30 min, they are asked to draw the same figure based on their memory. The Complex Figure Test assesses the subject's ability to remember a 2-dimensional figure presented briefly. The scoring system used includes scores related to location, accuracy and organization. Higher score correlates to better visual memory.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboVisual Memory Test: Complex Figure Delayed Recall; Number of Points10.6 number of pointsStandard Error 1.8
NovasoyVisual Memory Test: Complex Figure Delayed Recall; Number of Points13.4 number of pointsStandard Error 1.8
Secondary

Cognitive Outcomes-Global Cognition : Mini-Mental State Examination (MMSE) Score

During the MMSE, a health professional asks a participant a series of questions designed to test memory, ability to solve simple problems and other thinking skills. The maximum MMSE score - 30 points. Score of 20 to 24 - mild dementia, 13 to 20 - moderate dementia, and \<12 indicates severe dementia. On average, the MMSE score of a person with Alzheimer's declines about 2 to 4 points each year.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboCognitive Outcomes-Global Cognition : Mini-Mental State Examination (MMSE) Score21.3 score on a scaleStandard Deviation 1
NovasoyCognitive Outcomes-Global Cognition : Mini-Mental State Examination (MMSE) Score23.4 score on a scaleStandard Deviation 1
Secondary

Cognitive Outcomes - Visual Motor : Complex Figure Copy; Number of Points

Visual memory will be evaluated by Complex Figure copy test. The Complex Figure Test assesses the subject's ability to copy a 2-dimensional figure. The scoring system used include scores related to location, accuracy and organization. Higher score correlates to better visual memory.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboCognitive Outcomes - Visual Motor : Complex Figure Copy; Number of Points27.6 number of pointsStandard Error 1.1
NovasoyCognitive Outcomes - Visual Motor : Complex Figure Copy; Number of Points29.0 number of pointsStandard Error 1.1
Secondary

Cognitive Outcomes - Visual Motor : Time to Complete Grooved Pegboard Test Using the Dominant Hand

The Grooved Pegboard is a dexterity test consisting of 25 holes with randomly positioned slots. Pegs with a key on one side must be rotated to match the hole before they can be inserted. Participants are instructed to place all pegs into the 25 holes, picking up one at a time, and using just one hand. They use their dominant hand. Time taken to finish the test inversely correlates to the cognitive ability.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboCognitive Outcomes - Visual Motor : Time to Complete Grooved Pegboard Test Using the Dominant Hand134.3 time in secondsStandard Error 17.6
NovasoyCognitive Outcomes - Visual Motor : Time to Complete Grooved Pegboard Test Using the Dominant Hand149.8 time in secondsStandard Error 16.6
Secondary

Cognitive Outcomes - Visual Motor : Time to Complete Grooved Pegboard Test Using the Non-Dominant Hand

The Grooved Pegboard is a dexterity test consisting of 25 holes with randomly positioned slots. Pegs with a key on one side must be rotated to match the hole before they can be inserted. Participants are instructed to place all pegs into the 25 holes, picking up one at a time, and using just one hand. They use their non-dominant hand. Time taken to finish the test inversely correlates to the cognitive ability.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboCognitive Outcomes - Visual Motor : Time to Complete Grooved Pegboard Test Using the Non-Dominant Hand161.8 time in secondsStandard Error 24.4
NovasoyCognitive Outcomes - Visual Motor : Time to Complete Grooved Pegboard Test Using the Non-Dominant Hand156 time in secondsStandard Error 22.4
Secondary

Geriatric Depression Scale-Study Partner Report

Study partner is someone who has frequent contact with the subject (e.g. an average of 10 hours per week or more), and can accompany the subject to all clinic visits for the duration of the protocol. Study partner will report a short form GDS consisting of 15 questions. Out of 15 items, 10 indicate the presence of depression when answered positively, while the rest (question numbers 1, 5, 7, 11, 13) indicate depression when answered negatively. Scores of 0-4 are considered normal, depending on age, education, and complaints; Scores of 5-8 indicate mild depression; 9-11 indicate moderate depression; and Scores of 12-15 indicate severe depression. The Short Form is more easily used by physically ill and mildly to moderately demented patients who have short attention spans and/or feel easily fatigued. It takes about 5 to 7 minutes to complete.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboGeriatric Depression Scale-Study Partner Report5.2 score on a scaleStandard Error 0.7
NovasoyGeriatric Depression Scale-Study Partner Report6.3 score on a scaleStandard Error 0.7
Secondary

Geriatric Depression Scale-Subject Report

Geriatric Depression Scale (GDS) has been tested and used extensively with the older population to measure depression. Subject will self-report a short form GDS consisting of 15 questions. Out of 15 items, 10 indicate the presence of depression when answered positively, while the rest (question numbers 1, 5, 7, 11, 13) indicate depression when answered negatively. Scores of 0-4 are considered normal, depending on age, education, and complaints; Scores of 5-8 indicate mild depression; 9-11 indicate moderate depression; and Scores of 12-15 indicate severe depression. The Short Form is more easily used by physically ill and mildly to moderately demented patients who have short attention spans and/or feel easily fatigued. It takes about 5 to 7 minutes to complete

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboGeriatric Depression Scale-Subject Report2.1 score on a scaleStandard Error 0.6
NovasoyGeriatric Depression Scale-Subject Report3.3 score on a scaleStandard Error 0.6
Secondary

Multiple Mood States: Profile of Mood States (POMS)-Anger Scale

Anger scale is one of the subscale of POMS. Tension scale has 12 items and scores ranges from 0-48. Higher score indicates more anger issues.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboMultiple Mood States: Profile of Mood States (POMS)-Anger Scale6.8 score on a scaleStandard Error 1.4
NovasoyMultiple Mood States: Profile of Mood States (POMS)-Anger Scale8.3 score on a scaleStandard Error 1.4
Secondary

Multiple Mood States: Profile of Mood States (POMS)-Confusion Scale

Confusion scale is one of the subscale of POMS. Confusion scale has 7 items and scores ranges from 0-28. Higher score indicates more severe outcomes.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboMultiple Mood States: Profile of Mood States (POMS)-Confusion Scale15.5 score on a scaleStandard Error 1.1
NovasoyMultiple Mood States: Profile of Mood States (POMS)-Confusion Scale14 score on a scaleStandard Error 1.1
Secondary

Multiple Mood States: Profile of Mood States (POMS)-Depression Scale

Depression scale is one of the subscale of POMS. Depression scale has 15 items and scores ranges from 0-60. Higher score indicates more severe depression.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboMultiple Mood States: Profile of Mood States (POMS)-Depression Scale9 score on a scaleStandard Error 1.8
NovasoyMultiple Mood States: Profile of Mood States (POMS)-Depression Scale11.4 score on a scaleStandard Error 1.7
Secondary

Multiple Mood States: Profile of Mood States (POMS)-Fatigue Scale

Fatigue scale is one of the subscale of POMS. Tension scale has 7 items and scores ranges from 0-28. Higher score indicates more fatigue.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboMultiple Mood States: Profile of Mood States (POMS)-Fatigue Scale10.3 score on a scaleStandard Error 1.2
NovasoyMultiple Mood States: Profile of Mood States (POMS)-Fatigue Scale10.3 score on a scaleStandard Error 1.2
Secondary

Multiple Mood States: Profile of Mood States (POMS)-Tension Scale

Tension scale is one of the subscale of POMS. Tension scale has 9 items and scores ranges from 0-36. Higher score indicates more severe outcomes.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboMultiple Mood States: Profile of Mood States (POMS)-Tension Scale8.2 score on a scaleStandard Error 1.3
NovasoyMultiple Mood States: Profile of Mood States (POMS)-Tension Scale9.3 score on a scaleStandard Error 1.3
Secondary

Multiple Mood States: Profile of Mood States (POMS)-Vigor Scale

Vigor scale is one of the subscale of POMS. Vigor scale has 8 items and scores ranges from 0-32. Higher score indicates more severe outcomes.

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
PlaceboMultiple Mood States: Profile of Mood States (POMS)-Vigor Scale12.4 score on a scaleStandard Error 1.1
NovasoyMultiple Mood States: Profile of Mood States (POMS)-Vigor Scale12.0 score on a scaleStandard Error 1.1
Secondary

Number of Participants With ApoE4 Allele

The epsilon-4 allele of the apolipoprotein E gene (APOE4) has been consistently associated with a greater risk of Alzheimer's disease (AD) as well as an earlier onset of AD. Determination of apolipoprotein E (APOE) genotype was performed on a non-fasting blood sample collected at Baseline, using standard Polymerase chain reaction (PCR) and DNA sequencing techniques in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. DNA extracted from whole blood was amplified by PCR using specific primers for the ApoE gene and the DNA then sequenced and analyzed for genotype using the FinchTV program (Version 1.3; Geospiza, Inc.)

Time frame: Baseline

Population: Older adults with Alzheimer's disease

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PlaceboNumber of Participants With ApoE4 Allele15 Participants
NovasoyNumber of Participants With ApoE4 Allele16 Participants
Secondary

Plasma Concentrations of Estradiol at 3 Month

Estradiol assay will be performed on non-fasting blood samples collected at baseline using an enzyme immunoassay kit.

Time frame: At 3 month

Population: Estradiol analysis done by the same investigator as part of another project with different subjects (PMID: 9054783 linked in the citation), did not show any change in the estradiol levels. Based on that, investigators did not see the justification for running these analyses in the current study. No estradiol analyses were performed for this study.

Secondary

Plasma Concentrations of Estradiol at 6 Month

Estradiol assay will be performed on non-fasting blood samples collected at baseline using an enzyme immunoassay kit.

Time frame: At 6 month

Population: Estradiol analysis done by the same investigator as part of another project with different subjects (PMID: 9054783 linked in the citation), did not show any change in the estradiol levels. Based on that, investigators did not see the justification for running these analyses in the current study. No estradiol analyses were performed for this study.

Secondary

Plasma Concentrations of Estradiol at Baseline

Estradiol assay will be performed on non-fasting blood samples collected at baseline using an enzyme immunoassay kit.

Time frame: baseline

Population: Estradiol analysis done by the same investigator as part of another project with different subjects (PMID: 9054783 linked in the citation), did not show any change in the estradiol levels. Based on that, investigators did not see the justification for running these analyses in the current study. No estradiol analyses were performed for this study.

Secondary

Plasma Concentrations of Isoflavones at Baseline

Isoflavone assays will be performed on non-fasting blood samples collected at baseline. Novasoy capsules predominantly contain purified glycoside forms of isoflavones known genistein and diadzein. The plasma level of genistein and diadzine will be measured in the participants plasma.There is large inter-individual variations in the extent of intestinal metabolism, even when the quantity of isoflavone intake is standardized. Equol is a metabolite of isoflavones. Equol has high biological efficacy. Therefore, along with genistein and diadzein, plasma levels of equol will be measured to understand the isoflavone metabolism in the participants.

Time frame: baseline

Population: Data is unavailable for 2 subject from placebo group and 1 subjects from Novasoy group

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboPlasma Concentrations of Isoflavones at BaselineDaidzein2.8 ng/mlStandard Deviation 6.1
PlaceboPlasma Concentrations of Isoflavones at BaselineEquol0.3 ng/mlStandard Deviation 1.5
PlaceboPlasma Concentrations of Isoflavones at BaselineGenistein4.8 ng/mlStandard Deviation 11.4
NovasoyPlasma Concentrations of Isoflavones at BaselineGenistein1.5 ng/mlStandard Deviation 2.6
NovasoyPlasma Concentrations of Isoflavones at BaselineDaidzein1.3 ng/mlStandard Deviation 2.5
NovasoyPlasma Concentrations of Isoflavones at BaselineEquol0.1 ng/mlStandard Deviation 0.5
Secondary

Plasma Concentrations of Isoflavones at Month 3

Isoflavone assays will be performed on non-fasting blood samples collected at month 3. Novasoy capsules predominantly contain purified glycoside forms of isoflavones known genistein and diadzein. The plasma level of genistein and diadzine will be measured in the participants plasma.There is large inter-individual variations in the extent of intestinal metabolism, even when the quantity of isoflavone intake is standardized. Equol is a metabolite of isoflavones. Equol has high biological efficacy. Therefore, along with genistein and diadzein, plasma levels of equol will be measured to understand the isoflavone metabolism in the participants.

Time frame: At month 3

Population: Data is unavailable for 1 subject from each group

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboPlasma Concentrations of Isoflavones at Month 3Genistein2.1 ng/mlStandard Deviation 3.7
PlaceboPlasma Concentrations of Isoflavones at Month 3Daidzein1.1 ng/mlStandard Deviation 2.3
PlaceboPlasma Concentrations of Isoflavones at Month 3Equol0.2 ng/mlStandard Deviation 0.5
NovasoyPlasma Concentrations of Isoflavones at Month 3Genistein2777.7 ng/mlStandard Deviation 188.4
NovasoyPlasma Concentrations of Isoflavones at Month 3Daidzein197.3 ng/mlStandard Deviation 150.5
NovasoyPlasma Concentrations of Isoflavones at Month 3Equol20.3 ng/mlStandard Deviation 50.7
Secondary

Plasma Concentrations of Isoflavones at Month 6

Isoflavone assays will be performed on non-fasting blood samples collected at month 6. Novasoy capsules predominantly contain purified glycoside forms of isoflavones known genistein and diadzein. The plasma level of genistein and diadzine will be measured in the participants plasma.There is large inter-individual variations in the extent of intestinal metabolism, even when the quantity of isoflavone intake is standardized. Equol is a metabolite of isoflavones. Equol has high biological efficacy. Therefore, along with genistein and diadzein, plasma levels of equol will be measured to understand the isoflavone metabolism in the participants.

Time frame: At month 6

Population: Data is unavailable for 1 subject from placebo group and 3 subjects from Novasoy group

ArmMeasureGroupValue (MEAN)Dispersion
PlaceboPlasma Concentrations of Isoflavones at Month 6Genistein15.6 ng/mlStandard Deviation 35.4
PlaceboPlasma Concentrations of Isoflavones at Month 6Daidzein10.6 ng/mlStandard Deviation 37.8
PlaceboPlasma Concentrations of Isoflavones at Month 6Equol0.1 ng/mlStandard Deviation 0.6
NovasoyPlasma Concentrations of Isoflavones at Month 6Equol19.6 ng/mlStandard Deviation 40.5
NovasoyPlasma Concentrations of Isoflavones at Month 6Genistein338.6 ng/mlStandard Deviation 308.8
NovasoyPlasma Concentrations of Isoflavones at Month 6Daidzein206.6 ng/mlStandard Deviation 156.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026